Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963203 | 0.92 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5963084 | 0.92 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5963020 | 0.92 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7595624 | 0.85 | ADORA3 (0.52) | ADORA2AADORA2BADORA3ADORA1LMNA | |
| SCHEMBL5963035 | 0.85 | ADORA2A (0.70) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5963222 | 0.85 | ADORA2A (0.70) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL2344057 | 0.84 | ADORA2A (0.70) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5963000 | 0.84 | ADORA2A (0.70) | ADORA2AADORA2BADORA3 | |
| SCHEMBL5963147 | 0.84 | ADORA2A (0.70) | ADORA2AADORA2BADORA3 | |
| SCHEMBL8161283 | 0.84 | ADORA2A (0.70) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101993-B1 | Oligonucleotides containing 2′-O-modified purines | ISIS PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | ADORA2A 132/4885ADORA2B 301/4885ADORA3 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.